Author + information
- aWhitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts
- bEvans Department of Internal Medicine, Boston University School of Medicine, Boston, Massachusetts
- cCardiovascular Section, Boston University School of Medicine, Boston, Massachusetts
- ↵∗Address for correspondence:
Dr. Flora Sam, Whitaker Cardiovascular Institute, Cardiovascular Medicine Section, Boston University School of Medicine, 700 Albany Street, W507, Boston, Massachusetts 02118.
Heart failure with preserved ejection fraction (HFpEF) is characterized by signs and symptoms of heart failure in the presence of a normal left ventricular ejection fraction. Despite accounting for up to 50% of all clinical presentations of heart failure, the mechanisms implicated in HFpEF are poorly understood, thus precluding effective therapy. The pathophysiological heterogeneity in the HFpEF phenotype also contributes to this disease and likely to the absence of evidence-based therapies. Limited access to human samples and imperfect animal models that completely recapitulate the human HFpEF phenotype have impeded our understanding of the mechanistic underpinnings that exist in this disease. Aging and comorbidities such as atrial fibrillation, hypertension, diabetes and obesity, pulmonary hypertension, and renal dysfunction are highly associated with HFpEF, yet the relationship and contribution between them remains ill-defined. This review discusses some of the distinctive clinical features of HFpEF in association with these comorbidities and highlights the advantages and disadvantage of commonly used murine models used to study the HFpEF phenotype.
Dr. Sam has received a grant from the National Institutes of Health (HL117153). Dr. Valero-Muñoz has received a grant from the American Heart Association (17POST33660439). Dr. Backman has reported that he has no relationships relevant to the content of this paper to report.
All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.
- Received May 30, 2017.
- Revision received July 25, 2017.
- Accepted July 27, 2017.
- 2017 The Authors